Stockreport

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc.  (MAIA) 
PDF 16 patients surpassed 12-month survival follow-upTHIO's substantial survival benefit in third line surpasses comparable standard-of-care overall survival of 5.8 monthsMe [Read more]